Bayer AG (BAYZF)
50.53
+1.04
(+2.11%)
USD |
OTCM |
Oct 06, 16:00
Bayer Enterprise Value : 88.82B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 88.82B |
| October 05, 2026 | 87.79B |
| October 02, 2026 | 91.04B |
| October 01, 2026 | 88.33B |
| September 30, 2026 | 93.38B |
| September 29, 2026 | 93.55B |
| September 28, 2026 | 95.76B |
| September 25, 2026 | 94.85B |
| September 24, 2026 | 94.46B |
| September 23, 2026 | 94.95B |
| September 22, 2026 | 94.79B |
| September 21, 2026 | 94.32B |
| September 18, 2026 | 93.21B |
| September 17, 2026 | 94.57B |
| September 16, 2026 | 94.57B |
| September 15, 2026 | 95.60B |
| September 14, 2026 | 95.60B |
| September 11, 2026 | 94.68B |
| September 10, 2026 | 94.68B |
| September 09, 2026 | 94.68B |
| September 08, 2026 | 94.68B |
| September 04, 2026 | 94.68B |
| September 03, 2026 | 94.75B |
| September 02, 2026 | 94.75B |
| September 01, 2026 | 94.75B |
| Date | Value |
|---|---|
| August 31, 2026 | 94.53B |
| August 28, 2026 | 94.53B |
| August 27, 2026 | 94.53B |
| August 26, 2026 | 95.52B |
| August 25, 2026 | 95.52B |
| August 24, 2026 | 94.36B |
| August 21, 2026 | 94.14B |
| August 20, 2026 | 94.61B |
| August 19, 2026 | 92.83B |
| August 18, 2026 | 92.83B |
| August 17, 2026 | 92.83B |
| August 14, 2026 | 92.83B |
| August 13, 2026 | 92.83B |
| August 12, 2026 | 94.15B |
| August 11, 2026 | 95.06B |
| August 10, 2026 | 95.06B |
| August 07, 2026 | 95.06B |
| August 06, 2026 | 95.06B |
| August 05, 2026 | 95.20B |
| August 04, 2026 | 93.86B |
| August 03, 2026 | 92.36B |
| July 31, 2026 | 93.45B |
| July 30, 2026 | 93.97B |
| July 29, 2026 | 91.97B |
| July 28, 2026 | 91.05B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SenesTech, Inc. | 1.896M |
| Dermapharm Holding SE | 3.471B |
| Johnson & Johnson | 641.85B |
| Merck & Co., Inc. | 397.17B |
| Pfizer Inc. | 208.52B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 266.26M |
| Revenue (Quarterly) | 12.64B |
| Total Expenses (Quarterly) | 12.39B |
| EPS Diluted (Quarterly) | 0.2592 |
| Gross Profit Margin (Quarterly) | 58.24% |
| Profit Margin (Quarterly) | 2.11% |
| Earnings Yield | -4.05% |
| Operating Earnings Yield | 14.73% |
| Normalized Earnings Yield | 3.910 |